Lexicon Pharmaceuticals (LXRX) Amortizatization of Intangibles (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Amortizatization of Intangibles of $562000.0 for Q1 2026, down 57.62% year-over-year from $1.3 million in Q1 2025, and up 27.73% on a QoQ basis from $440000.0 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) has 5 years of Amortizatization of Intangibles data on file, last reported at $562000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 57.62% year-over-year to $562000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 68.07% YoY) and the FY2025 annual result came in at $3.7 million, down 60.11% from the prior year.
- Amortizatization of Intangibles grew to $562000.0 in Q1 2026 per LXRX's latest filing, from $440000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $3.3 million in Q2 2024 and bottomed at $440000.0 in Q4 2025.
- The 4-year median for Amortizatization of Intangibles is $1.4 million (2024), against an average of $1.6 million.
- Peak annual rise in Amortizatization of Intangibles reached 5.22% in 2025, while the deepest fall reached 76.68% in 2025.
- Tracing LXRX's Amortizatization of Intangibles over 4 years: stood at $2.0 million in 2023, then decreased by 5.84% to $1.9 million in 2024, then slumped by 76.68% to $440000.0 in 2025, then increased by 27.73% to $562000.0 in 2026.
- Per Business Quant, the three latest LXRX Amortizatization of Intangibles figures stand at $562000.0 (Q1 2026), $440000.0 (Q4 2025), and $732000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Lexicon Pharmaceuticals | 872.52 Mn | 701.87 Mn | 20.99 Mn | 562,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 562,000.00 |
| Mar 31, 2026 | 562,000.00 |
| Dec 31, 2025 | 440,000.00 |
| Dec 31, 2025 | 440,000.00 |
| Sep 30, 2025 | 732,000.00 |
| Sep 30, 2025 | 732,000.00 |
| Jun 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.33 Mn |
| Mar 31, 2025 | 1.33 Mn |
| Dec 31, 2024 | 1.89 Mn |
| Dec 31, 2024 | 1.89 Mn |
| Sep 30, 2024 | 2.71 Mn |
| Sep 30, 2024 | 2.71 Mn |
| Jun 30, 2024 | 3.31 Mn |
| Jun 30, 2024 | 3.31 Mn |
| Mar 31, 2024 | 1.40 Mn |
| Mar 31, 2024 | 1.40 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Sep 30, 2010 | 2.60 Mn |
| Sep 30, 2010 | 2.60 Mn |